Secukinumab (Cosentyx®) Effectiveness in Axial Spondyloarthritis and Psoriatic Arthritis Patients Using Artificial Intelligence (SpAINET): Spanish Multicenter, Retrospective, Real World Evidence Study
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Aged ≥ 18 years.
Diagnosed with axSpA or PsA.
Had received or are receiving bDMARD, independently of the line of treatment, from January 2018 to data collection.
Had at least 3 months follow up from first bDMARD administration.
Patients with EHRs.
You may not be if
Receiving bDMARD within a clinical trial from January 2018 to data collection.
Clareo Health | Secukinumab (Cosentyx®) Effectiveness in Axial Spondyloarthritis and Psoriatic Arthritis Patients Using Artificial Intelligence (SpAINET): Spanish Multicenter, Retrospective, Real World Evidence Study
